Sunitinib (Sutent) inhibits platelet-derived growth factor receptors and VEGF receptors as a multiple receptor tyrosine kinase inhibitor, which was approved by the U.S. Food and Drug Administration for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumours33. This evidence concerns the gene NTRK1 and hereditary clear cell renal cell carcinoma.